A Study of DXC018 in Patients With Advanced Solid Tumors

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC018 in participants with Advanced Solid Tumors.
Epistemonikos ID: 05dc93b014bddcd89f4efca0673d28009641a2e2
First added on: Oct 01, 2026